Fosamax Tablet
Product Images NDC 78206-135

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Fosamax (NDC 78206-135). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Organon Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Of Alendronate Sodium Chemical Structure (Fosamax 01)

Chemical structure of alendronate sodium showing a central carbon atom bonded to amino and phosphonate groups with associated sodium and water molecules. The structure illustrates the molecular composition of the active ingredient in FOSAMAX 70 mg tablets by Organon LLC.*

FDA Label Image

Image Of Figure 1 (Fosamax 02)

A line chart showing the cumulative incidence of hip fractures over 36 months comparing FOSAMAX and placebo in patients with radiographic vertebral fractures at baseline. The y-axis represents cumulative incidence percentage, and the x-axis shows time in months. The graph illustrates lower incidence rates with FOSAMAX compared to placebo throughout the study period.*

FDA Label Image

Image Of Figure 2 (Fosamax 03)

A bar graph titled 'Osteoporosis Treatment Studies in Postmenopausal Women' showing the increase in bone mineral density (BMD) at three years with FOSAMAX 10 mg/day. The graph compares mean percentage BMD increase relative to placebo at the lumbar spine, femoral neck, and trochanter between U.S. and multinational study populations.*

FDA Label Image

Image Of Figure 3 (Fosamax 04)

A chart showing the time course effect of FOSAMAX 10 mg/day versus placebo on lumbar spine bone mineral density (BMD) percent change from baseline in postmenopausal women. The chart compares data from a U.S. study and a multinational study over 36 months, depicting mean percent change with standard error for FOSAMAX and placebo groups.*

FDA Label Image

Image Of Figure 4 (Fosamax 05)

Two bar graphs titled 'Osteoporosis Prevention Studies in Postmenopausal Women' showing change in bone mineral density (BMD) from baseline over 2-year and 3-year periods. Each graph compares BMD percentage changes (+SE) at lumbar spine, femoral neck, trochanter, and total body between Fosamax 5mg/day and placebo groups.*

FDA Label Image

Image Of Figure 5 (Fosamax 06)

A bar chart illustrating the mean percentage increase in Bone Mineral Density (BMD) relative to placebo after one year of FOSAMAX 5 mg/day treatment in glucocorticoid-treated patients. It compares results between U.S. and multinational populations at three anatomical sites: Lumbar Spine, Femoral Neck, and Trochanter, with error bars indicating standard deviation.*

FDA Label Image

Image Of Figure 6 (Fosamax 07)

A line graph showing the effect of FOSAMAX (alendronate sodium) 40 mg/day versus placebo or etidronate 400 mg/day on serum alkaline phosphatase levels in patients with Paget's disease of bone over 6 months. The graph presents mean percentage change from baseline with error bars and sample sizes for each group in both multinational and U.S. studies.*

FDA Label Image

Principal Display Panel (4 Tablet Blister Pack)

Packaging label for Once Weekly FOSAMAX 70 mg tablets (Alendronate Sodium Tablets) by Organon LLC. The label includes dosage and storage instructions, a space for a prescription label, and mentions that each tablet contains 91.37 mg alendronate sodium (70 mg free acid equivalent). The label also indicates a four-tablet count and highlights dispensing the enclosed Medication Guide to each patient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.